Description
Lenakast 25 mg contains Lenalidomide, a potent immunomodulatory agent (IMiD) widely used in hematologic malignancies. It is administered orally and commonly prescribed in combination with other therapies such as dexamethasone or monoclonal antibodies.
🔬 Mechanism of Action
Lenalidomide exerts multiple anticancer effects:
- Enhances T-cell and natural killer (NK) cell activity
- Inhibits tumor cell proliferation
- Reduces angiogenesis (formation of new blood vessels)
- Promotes apoptosis (cancer cell death)
This multi-targeted mechanism makes it effective in various blood cancers.
💊 Indications
Lenakast 25 mg is indicated for:
- Multiple Myeloma (MM) (newly diagnosed and relapsed/refractory)
- Myelodysplastic Syndromes (MDS) with deletion 5q abnormality
- Mantle Cell Lymphoma (MCL) after prior therapy
- Follicular Lymphoma (FL) in combination therapy
📌 Key Features
- Strength: 25 mg
- Dosage Form: Oral capsule
- Therapeutic Class: Immunomodulatory Agent (IMiD)
- Administration: Taken orally, typically once daily for 21 days followed by 7 days off (28-day cycle), as prescribed
- Monitoring: Regular complete blood count (CBC), kidney function, and pregnancy testing required
⚕️ Benefits
- Enhances immune-mediated tumor destruction
- Improves progression-free and overall survival in multiple myeloma
- Oral therapy for patient convenience
- Compatible with combination regimens
⚠️ Precautions
- Risk of neutropenia and thrombocytopenia
- Increased risk of thromboembolic events
- Strict pregnancy prevention program required (teratogenic risk)
- Dose adjustments may be needed in renal impairment
- Use strictly under hematologist/oncologist supervision
Lenakast 25 mg (Lenalidomide Capsules) is a cornerstone therapy in modern hematology, offering effective immune-based treatment for multiple myeloma and related blood disorders when administered under specialized medical guidance.
